Результаты поиска

Time-restricted versus standard-duration immunosuppression after allogeneic hematopoietic stem cell transplantation: Results of the prospective randomized HOVON-96 trial.

Cyclosporine A combined with mycophenolate mofetil (CsA/MMF) has become an established regimen for the prevention of graft-versus-host disease (GVHD) following non-myeloablative (NMA) allogeneic hematopoietic stem cell transplantation (alloHSCT). However, the optimal duration of immunosuppression (IS) has not yet been defined and overtreatment is of concern. We hypothesized that time-restricted IS with CsA/MMF would increase the proportion of patients with non-severe GVHD compared to standard-duration IS, thereby resulting in reduction of the relapse rate and improvement of progression-free su

Совпадение в полном тексте источника
… Both sirolimus and tacrolimus have been studied, either in addition to standard CsA/MMF or instead of CsA. … Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil‐based graft‐versus‐host disease prophylaxis for patients after unrelated non‐myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol. 2019;6(8):e409‐e418. 31. …

Immunosuppressants/Immunomodulators and Malignancy.

Individuals with immunosuppressive conditions are at a higher risk of developing malignancies than those in the general population. Immunosuppression weakens tumor immunity, hinders the detection of pro-oncogenic cells, and activates oncogenic viruses. Malignancies arising in immunosuppressed patients tend to be aggressive, have a high incidence of virus-associated cancers, and are reversible in some cases. Notably, immunosuppressive agents influence the frequency and type of malignancies, as well as their clinicopathological features. Organ transplant recipients receive long-term immunosuppre

Совпадение в полном тексте источника
… In the 2000s, everolimus (EVL) and sirolimus (SRL) emerged as a mammalian target of rapamycin (mTOR) inhibitors [ 35 ]. … Sirolimus effects on cancer incidence after kidney transplantation: A meta-analysis. Cancer Med. 2015;4:1448–1459. doi: 10.1002/cam4.487. 54. Kauffman H.M., Cherikh W.S., Cheng Y., Hanto D.W., Kahan B.D. …

Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes.

Chronic graft-versus-host disease (cGVHD) is a major limitation to the long-term success of allogeneic hematopoietic cell transplantation (HCT). Our prior study of acute GVHD (aGVHD) defined distinct treatment-response groups based on the response to first-line corticosteroids: steroid-sensitive (SS), steroid-resistant (SR), and steroid-dependent (SD) aGVHDs. We conducted a retrospective, single-institution, cohort study to assess the incidence, risk factors, and clinical outcomes of patients with cGVHD after a previous diagnosis of SS, SD, or SR aGVHD, compared with those with no history of a

Совпадение в полном тексте источника
… year of HCT, diagnosis, donor type (matched sibling donor, matched URD, partially matched or mismatched URD, haploidentical, or UCB), prior autologous transplantation, conditioning intensity (MAC vs RIC), GVHD prophylaxis (cyclosporine [CsA] with methotrexate, CsA with mycophenolate mofetil [MMF], sirolimus … | 8 (8%) | 10 (10%) | 29 (19%) Conditioning intensity | | | | MAC | 194 (44%) | 45 (45%) | 44 (46%) | 61 (40%) RIC | 243 (56%) | 54 (55%) | 52 (54%) | 91 (60%) GVHD prophylaxis | | | | CsA/MTX | 77 (18%) | 20 (20%) | 12 (12%) | 19 (12%) CsA/MMF | 246 (56%) | 66 (67%) | 78 (81%) | 105 (69%) Sirolimus …

Evaluation and Management of Bacterial and Fungal Infections Occurring in Patients with a Hematological Malignancy: A 2011 Update

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… The more difficult clinical scenario is the management of patients who are to receive concomitant voriconazole or posaconazole and sirolimus. … Yet, the need to prescribe voriconazole/posaconazole for some patients receiving sirolimus is critical. Thus it is suggested that by reducing the sirolimus dose by 90 % and carefully monitoring serum levels, these agents can be successfully co-administrated. …

Drug Repurposing for Cancer Treatment: A Comprehensive Review.

Cancer ranks among the primary contributors to global mortality. In 2022, the global incidence of new cancer cases reached about 20 million, while the number of cancer-related fatalities reached 9.7 million. In Saudi Arabia, there were 13,399 deaths caused by cancer and 28,113 newly diagnosed cases of cancer. Drug repurposing is a drug discovery strategy that has gained special attention and implementation to enhance the process of drug development due to its time- and money-saving effect. It involves repositioning existing medications to new clinical applications. Cancer treatment is a therap

Совпадение в полном тексте источника
… Sirolimus, often known as rapamycin, is an FDA-approved inhibitor of the mTOR pathway employed for the prevention of rejection following renal transplantation. … The synergistic inhibition of colon tumor growth by a combination of sirolimus and metformin has been demonstrated by Mussin et al. in both in vitro and in vivo settings. …

Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: A multicenter, retrospective study.

Acute graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). This analysis of 168 patients (mean age, 54.8 years) from a multicenter, retrospective chart review describes the clinical course, treatment patterns, hospitalizations, and clinical outcomes of patients aged ≥12 years who developed grades II-IV acute GVHD after their first allogeneic HCT (January 1, 2014, to June 30, 2016) and were refractory to or dependent on corticosteroids. Between diagnosis and maximum grade (median, 6.0 days), 53.6% of pa

Совпадение в полном тексте источника
… | 108 (74.0) Methotrexate | 50 (48.5) | 17 (30.9) | 67 (45.9) Mycophenolate | 44 (42.7) | 23 (41.8) | 67 (45.9) Cyclosporine-based | 28 (27.2) | 7 (12.7) | 35 (24.0) Antithymocyte globulin | 13 (12.6) | 8 (14.5) | 21 (14.4) High-dose cyclophosphamide (posttransplant) | 1 (1.0) | 9 (16.4) | 10 (6.8) Sirolimus … Long-term outcome of allogeneic hematopoietic stem cell transplantation from unrelated donor using tacrolimus/sirolimus-based GVHD prophylaxis: Impact of HLA mismatch. Transplantation. 2020;104:1070–80. doi: 10.1097/TP.0000000000002932. 5. …

Association between the prognostic nutritional index and early mortality of AML patients after allogeneic HSCT: a retrospective cohort analysis.

BACKGROUND: Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is an effective treatment for Acute Myeloid Leukemia (AML). The pre-transplantation Prognostic Nutritional Index (PNI) plays a critical role in determining patient prognosis, however, its correlation with mortality within 180 days after SCT is currently unclear. OBJECTIVE: This study aimed to investigate the association between PNI and mortality within 180 days among AML patients who underwent HSCT. METHODS: We conducted a cohort study by retrospectively collecting data from AML patients who underwent HSCT. The PNI wa

Совпадение в полном тексте источника
… Successful treatment of upper limb superficial lymphatic malformation with topical sirolimus . Case Rep Dermatol Med . ( 2025 ) 2025 : 9574261 . doi: 10.1155/crdm/9574261 , PMID: 41458915 PMC12742332 3 Marzolini MAV Kayani I Carpenter B Laurence A McLornan D Raj K . … The addition of sirolimus to GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation: A meta-analysis of efficacy and safety . Front Oncol . ( 2021 ) 11 : 683263 . doi: 10.3389/fonc.2021.683263 , PMID: 34568015 PMC8458935 29 Sureda A Corbacioglu S Greco R Kroger N Carreras E eds. …

The Rise of Oncoendocrinology: How Modern Cancer Therapies Are Reshaping Endocrine Practice.

The emergence of immune checkpoint inhibitors, targeted therapies, CAR T-cell therapy, and antibody-drug conjugates has transformed modern oncology, significantly improving survival across a wide range of malignancies. However, these advances have also introduced a growing spectrum of endocrine and metabolic complications, redefining the scope of endocrine practice. Therapy-induced endocrinopathies, including thyroid dysfunction, hypophysitis, adrenal insufficiency, diabetes, pancreatitis, dyslipidemia, gonadal dysfunction, and metabolic syndrome, are recognized as clinically significant and o

Совпадение в полном тексте источника
… In addition to metabolic effects, mTOR inhibitors, particularly sirolimus, have been linked to male hypogonadism, marked by reduced testosterone levels, elevated gonadotropins, and impaired spermatogenesis. … Sirolimus-associated testicular toxicity: Detrimental but reversible. Transplantation. 2012;93:874–879. doi: 10.1097/TP.0b013e31824bf1f0. 66. Sirico M., D’Angelo A., Gianni C., Casadei C., Merloni F., De Giorgi U. Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy. …

Pulmonary and Hepatic Complications of Hematopoietic Cell Transplantation

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… The clinician initiating voriconazole or other antifungal “azole” therapy should be mindful of its impact on cytochrome p450-dependent drugs, including the calcineurin inhibitors tacrolimus and cyclosporine and the mTor inhibitor sirolimus. … When voriconazole is initiated, doses of tacrolimus and cyclosporine should be reduced by 50 %, with even greater dosing reduction (90 %) for sirolimus if being given in conjunction with voriconazole. …

Evolving Therapeutic Strategies in ANCA-Associated Vasculitis: Current Standards and Emerging Targets for GPA and MPA.

Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are severe autoimmune disorders characterized by necrotizing small-vessel inflammation, and are classified among anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). Standard induction therapy combines glucocorticoids (GCs) with rituximab (RTX) or cyclophosphamide (CYC), with growing emphasis on GC minimization and selective use of avacopan in patients at high risk of GC toxicity. For maintenance therapy, fixed-interval RTX generally outperforms conventional oral agents and biomarker-guided re-dosin

Совпадение в полном тексте источника
… In a retrospective review of a cohort of patients with subglottic stenosis (SGS), sirolimus was administered to explore its immunosuppressive and antifibrotic effects [ 208 ]. … Six patients were treated, five of whom had GPA; four of six tolerated sirolimus without significant adverse events and achieved a steroid-sparing effect. …

Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease.

AimTo assess the toxicity, tolerance, steroid-sparing capacity, effectiveness, and response rate to imatinib and dasatinib for the treatment of severe sclerotic chronic graft-vs-host disease (scGVHD).MethodsThis retrospective study analyzed 8 consecutive patients with severe refractory scGVHD who received salvage therapy with imatinib. Patients intolerant and/or refractory to imatinib received dasatinib treatment.Results7 patients discontinued imatinib treatment (1 achieved complete response, 5 were resistant and/or intolerant, and 1 developed grade IV neutropenia) and 1 patient achieved prolo

Совпадение в полном тексте источника
… novo , 10 | De novo , 7 IS before TKI | CyA 3mg/Kg/d, MMF 1gr/8h, CS | CyA 3mg/Kg/d, MMF 1gr/8h, CS, PUVA (10 sessions) | CyA 3mg/Kg/d, MMF 1gr/8h, CS | CyA 3mg/Kg/d, MMF 1gr/8h, CS | CyA 3mg/Kg/d, MMF 1gr/8h, CS | CsA 3mg/Kg/d, MMF 1gr/8h, CS | CyA 3mg/Kg/d, MMF 1gr/8h, CS | CyA 3mg/Kg/d, MMF 1gr/8h, Sirolimus … On sirolimus Percent CS reduction | 90% / 0% † | 100% | 100% | NA | 100% | 100% | 100% | NA (refractoriness and discontinued) TKI initiation , date | Dasatinib, July/09 | Dasatinib, December/09 | Dasatinib, October/09 | Imatinib, August/10 | Imatinib, February/10 | Imatinib, January/09 | Dasatinib, March …

Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.

Androgen receptor (AR) and PI3K/AKT/mTORC1 are major survival signals that drive prostate cancer to a lethal disease. Reciprocal activation of these oncogenic pathways from negative cross talks contributes to low/limited success of pathway-selective inhibitors in curbing prostate cancer progression. We report that the antibiotic salinomycin, a cancer stem cell blocker, is a dual-acting AR and mTORC1 inhibitor, inhibiting PTEN-deficient castration-sensitive and castration-resistant prostate cancer in culture and xenograft tumors. AR expression, its transcriptional activity, and androgen biosynt

Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.

BACKGROUND: The study design was a retrospective cohort study. The objective was to identify preoperative (preop) radiographic features that are associated with increased lordosis correction after transforaminal lumbar interbody fusion (TLIF). METHODS: We retrospectively reviewed a single surgeon series of TLIF performed at L4-5 since 2010. The surgical technique involved unilateral facetectomy and insertion of a banana-type cage. A total of 107 cases were available with plain radiographs, and 62 with a preop computed tomography (CT) scan. We compared segmental lordosis correction between the

Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.

BACKGROUND: Chronic renal failure (CRF) is associated with increased cardiovascular mortality, and medial vascular smooth muscle cell (VSMC) hypertrophy, proliferation, and calcification play a pivotal role in uremic vasculopathy. Glucose transporter-1 (GLUT1) facilitates the transport of glucose into VSMCs, and GLUT1 overexpression associated with high glucose influx leads to a stimulation of VSMC proliferation. However, the role of GLUT1 in uremic vasculopathy remains unclear. This study aimed to identify changes in the expression of GLUT1 in VSMCs in the setting of experimental uremia and i

FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.

FOXO3a, a well-known transcriptional regulator, controls a wide spectrum of biological processes. The phosphoinositide-3-kinase (PI3K)/Akt signaling pathway inactivates FOXO3a via phosphorylation-induced nuclear exclusion and degradation. A loss or gain of FOXO3a activity has been correlated with efficiency of chemotherapies in various cancers including oral squamous cell carcinoma (OSCC). Therefore, in the current study, we have investigated the FOXO3a activity modulating and antitumor effects of rapamycin and cisplatin in OSCC cells. Cisplatin inhibited proliferation and induced apoptosis in

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.

PURPOSE: Everolimus (RAD001, Novartis), an oral derivative of rapamycin, inhibits the mammalian target of rapamycin (mTOR), which regulates many aspects of cell growth and division. A phase I/II study was done to determine safety and efficacy of everolimus in patients with relapsed or refractory hematologic malignancies. EXPERIMENTAL DESIGN: Two dose levels (5 and 10 mg orally once daily continuously) were evaluated in the phase I portion of this study to determine the maximum tolerated dose of everolimus to be used in the phase II study. RESULTS: Twenty-seven patients (9 acute myelogenous l

High levels of serum β2-microglobulin predict severity of coronary artery disease.

BackgroundThe identification of new risk factors for coronary artery disease (CAD) is increasingly sought in an effort to tackle this threatening disease. β2-microglobulin (B2M) is reported to associate with peripheral arterial disease and adverse cardiovascular outcomes. However, the association between B2M and cardiovascular disease remains under-researched. This study evaluated the effects of B2M on CAD without renal dysfunction.MethodsOne thousand seven hundred sixty-two subjects (403 non-CAD subjects and 1,359 CAD subjects) were investigated. Fasting samples were collected to determine B2

Совпадение в полном тексте источника
… Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal … Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials. …

Metabolic reprogramming in cancer and senescence.

The rising trend in global cancer incidence has caused widespread concern, one of the main reasons being the aging of the global population. Statistical data show that cancer incidence and mortality rates show a clear upward trend with age. Although there is a commonality between dysregulated nutrient sensing, which is one of the main features of aging, and metabolic reprogramming of tumor cells, the specific regulatory relationship is not clear. This manuscript intends to comprehensively analyze the relationship between senescence and tumor metabolic reprogramming; as well as reveal the impac

Совпадение в полном тексте источника
… albumin‐bound nanoparticles | Neuroendocrine tumors, pancreatic neuroendocrine tumors | Phase 2 | NCT05997056 | Smetinib, sirolimus | Malignant peripheral nerve sheath tumor | Phase 2 | NCT03433183 | Sirolimus (loanword) | Progressive solid tumors | Phase 2 | NCT00877773 | Isomethepromazine, everolimus … | Her2 negative metastatic breast cancer | Phase 2 | NCT01520103 | Anastrozole, AZD2014 | Endometrial cancer, estrogen receptor positive breast cancer | Phase 2 | NCT02730923 | pf‐05212384, pf‐05212384, pf‐05212384 | Endometrial cancer | Phase 2 | NCT01420081 | Sirolimus (loanword) | Ovaries | Phase …

A Pathology Experience of Posttransplant Lymphoproliferative Disorder From One Tertiary Hospital: Pathology Concepts and Diagnostic Approach.

BACKGROUND: Solid organ transplantation and bone marrow/hematologic stem cell transplantation recipients face a heightened risk of developing malignancies or cancer as a result of immunosuppression. Posttransplant lymphoproliferative disorders (PTLD) are a range of disorders from benign lymphoid growth to lymphoma found post-transplant. Risk factors for PTLD include high immunosuppressive use and oncogenic effects of Epstein-Barr virus (EBV). There is a lack of comprehensive clinical and pathological documentation of PTLD cases among Saudi patients, and the available data are limited to a few

Совпадение в полном тексте источника
… The single case diagnosed with atypical paracortical lymphoid hyperplasia was controlled with sirolimus, with no disease recurrence for 9 years. … immunosuppressant medications | No show 5 | 26 years/F | HCV/renal transplant 1 year ago | Left kidney | PTLD, DLBCL | Positive | Involved | 9 | R-CHOP | No recurrence 6 | 3 years/M | HLH/BM transplant 2 years ago | Right cervical LN | Atypical paracortical hyperplasia | Negative | Not involved | 9 | Controlled on sirolimus …

Post-Transplant Cyclophosphamide for the Prevention of Graft-vs.-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Guide to Management for the Advanced Practitioner.

Cyclophosphamide remains a critical component to haploidentical transplant conditioning regimens. Post-transplant cyclophosphamide (PTCy) emerged as an effective component of graft-vs.-host disease (GVHD) prophylaxis in the nonmyeloablative haploidentical bone marrow transplant setting. The relative ease of administration compared with ex vivo manipulations and efficacy in reducing GVHD has led to increasing PTCy use in transplant centers around the world. The role of PTCy has expanded to haploidentical transplantation with myeloablative conditioning regimens and peripheral blood progenitor ce

Совпадение в полном тексте источника
… Traditional GVHD prophylaxis agents, such as calcineurin inhibitors and sirolimus, weaken alloreactive T cell activation, proliferation, and interleukin-2 production without causing apoptosis, which may lead to delayed induction of transplant tolerance ( Strauss et al., 2002 ). … Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. …